https://www.fastfrance.org/ 2026-04-03T18:41:54+00:00 https://www.fastfrance.org/testresultangelmansyndrome/ 2025-08-10T08:29:46+00:00 https://www.fastfrance.org/displayangelmansyndromeconnexion/ 2025-08-08T12:28:49+00:00 https://www.fastfrance.org/test-forminator/ 2025-08-03T16:21:58+00:00 https://www.fastfrance.org/map-of-french-as-people/ 2025-05-06T13:14:07+00:00 https://www.fastfrance.org/map-of-french-as-people-and-centers-of-expertise-to-conduce-clinical-trials/ 2025-05-06T12:52:11+00:00 https://www.fastfrance.org/map-of-as-people/ 2025-10-23T09:39:08+00:00 https://www.fastfrance.org/elevating-pullman-full-funnel-marketing-and-experiential-campaigns/ 2024-12-10T19:11:09+00:00 https://www.fastfrance.org/angelman-bi-dashboard/ 2025-06-16T13:20:49+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/congres-scientifique-fast-2024/ 2024-11-27T15:51:55+00:00 https://www.fastfrance.org/pour-famille-angelman/faq-fast-france/ 2024-11-27T12:43:18+00:00 https://www.fastfrance.org/pour-famille-angelman/faq-essais-cliniques-angelman/ 2024-11-27T12:38:44+00:00 https://www.fastfrance.org/pour-famille-angelman/faq-fast/ 2024-11-27T12:41:14+00:00 https://www.fastfrance.org/pour-famille-angelman/faq-syndrome-angelman/ 2024-11-27T12:39:29+00:00 https://www.fastfrance.org/internal-dashboard/ 2025-05-09T08:28:45+00:00 https://www.fastfrance.org/externaldash/ 2025-05-09T09:35:13+00:00 https://www.fastfrance.org/dossier-angelman/ 2025-11-19T10:48:01+00:00 https://www.fastfrance.org/pour-famille-angelman/cartographie-syndrome-angelman-france/ 2025-05-03T15:32:03+00:00 https://www.fastfrance.org/pour-famille-angelman/cartographie-angelman-france/ 2025-11-14T11:15:33+00:00 https://www.fastfrance.org/dossier-angelman/dossier-thematique-sur-la-ou-plutot-les-therapies-geniques/partie2-les-therapies-geniques-2/ 2024-11-27T11:19:08+00:00 https://www.fastfrance.org/dossier-angelman/dossier-thematique-sur-la-ou-plutot-les-therapies-geniques/partie1-un-peu-de-biologie/ 2024-11-27T11:15:02+00:00 https://www.fastfrance.org/dossier-angelman/dossier-thematique-sur-la-ou-plutot-les-therapies-geniques/ 2024-11-27T11:12:03+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/congres-scientifique-fast-2023/ 2024-11-27T12:47:12+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/pilier-4-accelerer-preparer-essais-cliniques/ 2023-09-29T08:50:12+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/pilier-3-therapies-avales/ 2024-11-27T16:55:26+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/pilier-2-activer-le-gene-paternel/ 2024-11-19T17:34:43+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/pilier-1-reparer-le-gene-maternel/ 2024-11-19T17:33:48+00:00 https://www.fastfrance.org/pour-famille-angelman/can-page/ 2024-11-27T12:33:32+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/congres-scientifique-fast-2022/ 2024-11-27T12:51:25+00:00 https://www.fastfrance.org/dossier-angelman/ionis-syndrome-dangelman/ 2024-11-27T12:10:09+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/congres-scientifique-fast-2021/ 2024-11-27T12:53:39+00:00 https://www.fastfrance.org/actualites-sur-le-syndrome-dangelman/ 2024-11-27T10:55:57+00:00 https://www.fastfrance.org/contact/ 2023-12-12T15:05:49+00:00 https://www.fastfrance.org/politique-de-confidentialite/ 2024-12-13T20:09:05+00:00 https://www.fastfrance.org/dossier-angelman/neuren-syndrome-dangelman/ 2024-11-27T12:11:57+00:00 https://www.fastfrance.org/dossier-angelman/ovid-therapeutics/ 2024-11-20T12:44:49+00:00 https://www.fastfrance.org/dossier-angelman/roche-genentech/ 2025-04-15T12:58:05+00:00 https://www.fastfrance.org/dossier-angelman/genetx-ultragenyx/ 2024-12-21T09:43:21+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/ 2025-11-19T13:34:53+00:00 https://www.fastfrance.org/pour-famille-angelman/ 2024-12-13T17:17:41+00:00 https://www.fastfrance.org/recherche-syndrome-dangelman/congres-scientifique-fast-2020/ 2024-11-27T12:54:29+00:00 https://www.fastfrance.org/a-propos-de-fast/ 2024-11-20T14:03:58+00:00 https://www.fastfrance.org/definition-syndrome-dangelman/tests-genetiques-syndrome-dangelman/ 2024-11-27T13:01:27+00:00 https://www.fastfrance.org/definition-syndrome-dangelman/signes-cliniques-syndrome-dangelman/ 2024-11-27T13:03:54+00:00 https://www.fastfrance.org/definition-syndrome-dangelman/ 2024-11-27T10:39:39+00:00 https://www.fastfrance.org/newsletter/ 2024-11-20T13:35:32+00:00 https://www.fastfrance.org/don-recherche-syndrome-d-angelman/ 2024-11-27T10:27:02+00:00 https://www.fastfrance.org/mise-a-jour-de-la-communaute-ion582-ionis-decembre-2025/ 2025-12-23T08:53:20+00:00 https://www.fastfrance.org/ultragenyx-annonce-le-premier-patient-traite-dans-letude-aurora-evaluant-le-gtx-102-chez-de-nouveaux-genotypes-et-groupes-dage-atteints-du-syndrome-dangelman/ 2025-11-19T13:26:27+00:00 https://www.fastfrance.org/mavrix-bio-annonce-le-premier-patient-traite-dans-lessai-ascend-as-evaluant-mvx-220-une-therapie-genique-experimentale-pour-le-syndrome-dangelman/ 2025-11-19T13:28:48+00:00 https://www.fastfrance.org/map-malaysia/ 2025-10-23T08:47:01+00:00 https://www.fastfrance.org/map-indonesia/ 2025-09-23T12:28:38+00:00 https://www.fastfrance.org/map-india/ 2025-09-23T12:16:48+00:00 https://www.fastfrance.org/map-brazil/ 2025-06-23T11:52:20+00:00 https://www.fastfrance.org/map-germany/ 2025-06-19T13:47:48+00:00 https://www.fastfrance.org/map-italy/ 2025-06-19T12:30:33+00:00 https://www.fastfrance.org/map-australia/ 2025-06-19T08:14:43+00:00 https://www.fastfrance.org/map-usa/ 2025-06-19T08:05:18+00:00 https://www.fastfrance.org/map-canada/ 2025-06-19T07:53:46+00:00 https://www.fastfrance.org/map-uk/ 2025-06-19T07:38:11+00:00 https://www.fastfrance.org/map-france/ 2025-06-17T15:08:16+00:00 https://www.fastfrance.org/map-latam/ 2025-06-19T06:51:12+00:00 https://www.fastfrance.org/map-spain/ 2025-06-17T14:14:23+00:00 https://www.fastfrance.org/map-poland/ 2025-06-17T14:18:29+00:00 https://www.fastfrance.org/test-fast-latam/ 2025-06-17T14:24:15+00:00 https://www.fastfrance.org/mavrix-bio-annonce-lapprobation-par-la-fda-dune-demande-dind-en-vue-de-lancer-une-premiere-etude-chez-lhomme-de-therapie-genique-pour-le-syndrome-dangelman/ 2025-05-12T17:10:46+00:00 https://www.fastfrance.org/un-chercheur-finance-par-le-programme-fast-met-en-evidence-limplication-de-lube3a-dans-differentes-maladies-neurodegeneratives/ 2025-04-24T07:47:23+00:00 https://www.fastfrance.org/oak-hill-bio-conclut-un-accord-de-licence-exclusif-avec-roche-pour-obtenir-les-droits-mondiaux-dun-traitement-potentiel-de-premier-ordre-pour-la-phase-3-pour-les-personnes-atteintes-du-syndrome-da/ 2025-04-15T12:53:27+00:00 https://www.fastfrance.org/fast-annonce-le-lancement-de-mavrix-bio-et-courageas-bio-pour-faire-progresser-les-therapies-experimentales-ciblant-les-genes-pour-le-syndrome-dangelman/ 2025-02-15T06:48:48+00:00 https://www.fastfrance.org/eye-angel-prise-de-rendez-vous/ 2025-04-04T09:26:51+00:00 https://www.fastfrance.org/le-programme-de-recherche-affilie-a-fast-a-lucla-recoit-58-millions-de-dollars-pour-faire-progresser-la-therapie-genique-du-syndrome-dangelman/ 2025-01-31T15:10:53+00:00 https://www.fastfrance.org/ultragenyx-annonce-la-prise-en-charge-du-premier-patient-de-letude-pivot-de-phase-3-aspire-evaluant-gtx-102-dans-le-syndrome-dangelman/ 2024-12-21T09:41:39+00:00 https://www.fastfrance.org/ionis-annonce-la-conception-dun-essai-pivot-de-phase-3-pour-ion582-dans-le-syndrome-dangelman/ 2024-11-11T12:05:19+00:00 https://www.fastfrance.org/neuren-pharma-annonce-des-resultats-positifs-pour-son-essai-de-phase-2-dans-le-syndrome-dangelman/ 2024-08-10T12:57:52+00:00 https://www.fastfrance.org/ionis-annonce-des-resultats-detailles-positifs-de-letude-halos-sur-ion582-chez-les-personnes-atteintes-du-syndrome-dangelman/ 2024-11-27T16:36:48+00:00 https://www.fastfrance.org/ultragenyx-annonce-le-succes-de-son-echange-de-fin-de-phase-2-avec-la-fda-pour-le-programme-gtx-102-sur-le-syndrome-dangelman/ 2024-11-27T16:24:13+00:00 https://www.fastfrance.org/fast-france-et-etude-sur-leye-tracking/ 2024-12-25T10:55:15+00:00 https://www.fastfrance.org/message-du-laboratoire-pour-la-communaute-angelman/ 2024-11-27T16:37:00+00:00 https://www.fastfrance.org/communique-de-presse-des-resultats-positifs-de-letude-de-phase-1-2a-de-ionis/ 2024-11-27T15:25:26+00:00 https://www.fastfrance.org/creation-du-comite-scientifique-de-fast-france/ 2024-11-27T15:42:21+00:00 https://www.fastfrance.org/bienvenue-a-fast-allemagne/ 2024-11-27T16:29:44+00:00 https://www.fastfrance.org/lettre-pour-la-communaute-suite-aux-resultats-intermediaires-positifs-de-lessai-clinique-de-phase-1-2-dultragenyx/ 2024-11-27T16:24:28+00:00 https://www.fastfrance.org/ultragenyx-annonce-des-donnees-interimaires-positives-de-phase-1-2-chez-des-patients-atteints-du-syndrome-dangelman-apres-traitement-par-gtx-102/ 2024-11-27T16:35:08+00:00 https://www.fastfrance.org/des-scientifiques-de-lucsf-ont-decouvert-une-methode-moins-invasive-dadministration-dans-le-traitement-prenatal-pour-le-syndrome-dangelman/ 2024-11-27T16:40:06+00:00 https://www.fastfrance.org/tous-en-bleu-pour-liad-2024/ 2024-11-27T15:40:46+00:00 https://www.fastfrance.org/ultragenyx-recoit-la-designation-prime-de-lagence-europeenne-des-medicaments-ema-pour-gtx-102/ 2024-11-27T16:24:41+00:00 https://www.fastfrance.org/iad-2024/ 2024-11-27T16:35:32+00:00 https://www.fastfrance.org/ultragenyx-annonce-la-fin-du-recrutement-pour-lessai-mondial-de-phase-1-2-de-gtx-102-chez-les-enfants-atteints-du-syndrome-dangelman/ 2024-11-27T16:24:54+00:00 https://www.fastfrance.org/un-cross-pour-pietro/ 2024-11-27T16:12:09+00:00 https://www.fastfrance.org/fast-uk-et-lintelligence-artificielle-comme-ressource-pour-la-communaute-angelman/ 2024-11-27T16:32:26+00:00 https://www.fastfrance.org/nos-enfants-sont-beaux/ 2024-11-27T16:15:17+00:00 https://www.fastfrance.org/grille-de-mots-croises-pour-la-newsletter-du-mois-de-novembre/ 2024-11-27T16:33:39+00:00 https://www.fastfrance.org/mise-a-jour-sur-aldebaran-par-le-laboratoire-roche/ 2024-11-27T15:30:21+00:00 https://www.fastfrance.org/evelyne-fait-le-marathon-de-new-york-pour-heloise-et-fast-france/ 2024-11-27T16:20:19+00:00 https://www.fastfrance.org/retour-succinct-sur-le-congres-fast-2023/ 2024-11-27T16:28:30+00:00 https://www.fastfrance.org/temoignage-de-marie-astrid-pour-hermione/ 2024-11-27T16:22:12+00:00 https://www.fastfrance.org/le-royaume-uni-approuve-la-therapie-dedition-genique-crispr-une-premiere-mondiale/ 2024-11-27T15:39:14+00:00 https://www.fastfrance.org/fast-france-est-membre-de-lern-ithaca/ 2024-11-27T16:15:53+00:00 https://www.fastfrance.org/mise-a-jour-dultragenyx-sur-le-programme-gtx-102/ 2023-10-18T07:16:17+00:00 https://www.fastfrance.org/la-foundation-for-angelman-syndrome-therapeutics-fait-progresser-un-candidat-a-la-therapie-genique-par-le-biais-detudes-permettant-lobtention-dune-ind-menees-en-partenariat-avec-luniversite-de/ 2024-11-27T15:27:06+00:00 https://www.fastfrance.org/le-nih-annonce-un-investissement-de-40m-pour-une-plateforme-dedition-genomique-sur-le-syndrome/ 2024-11-27T16:33:50+00:00 https://www.fastfrance.org/nouvelle-etude-financee-par-fast-sur-lactivite-du-facteur-neurotrophique-derive-du-cerveau/ 2024-11-27T15:38:40+00:00 https://www.fastfrance.org/une-nouvelle-etude-de-fast-et-abom-met-laccent-sur-la-fonction-motrice-en-tant-quaspect-critique-du-syndrome-dangelman/ 2023-10-07T07:51:27+00:00 https://www.fastfrance.org/agenda-du-congres-scientifique-2023-de-fast/ 2024-11-27T15:44:12+00:00 https://www.fastfrance.org/gtx-102-continue-de-montrer-son-innocuite-apres-une-annee-dutilisation/ 2024-11-27T15:36:20+00:00 https://www.fastfrance.org/la-voie-nasale-et-les-nanoparticules-dans-le-traitement-du-syndrome-dangelman/ 2024-11-27T15:36:31+00:00 https://www.fastfrance.org/webinar-du-18-juillet-2023-retour-sur-les-essais-cliniques-en-france/ 2024-11-27T15:31:42+00:00 https://www.fastfrance.org/subvention-clinical-trial-2023/ 2024-11-27T16:29:06+00:00 https://www.fastfrance.org/revenons-sur-les-genotypes-upd-icd-et-mosaique/ 2024-11-27T15:36:44+00:00 https://www.fastfrance.org/la-therapie-par-arn-restaure-la-fonction-des-genes-chez-les-singes-modelisant-le-syndrome-dangelman/ 2024-11-27T15:37:05+00:00 https://www.fastfrance.org/nouvelle-publication-permettant-devaluer-leeg-comme-un-biomarqueur-sur-le-syndrome-dangelman/ 2024-11-27T15:33:02+00:00 https://www.fastfrance.org/un-traitement-sur-le-syndrome-de-rett/ 2024-11-27T15:28:58+00:00 https://www.fastfrance.org/en-apprendre-plus-sur-le-pilier-4-de-la-strategie-de-fast/ 2024-11-27T16:22:23+00:00 https://www.fastfrance.org/les-therapies-avales-sur-le-syndrome-dangelman/ 2023-02-06T10:14:07+00:00 https://www.fastfrance.org/communique-de-necker-sur-les-essais/ 2024-11-27T15:43:37+00:00 https://www.fastfrance.org/apprendre-sur-la-seconde-piste-avec-les-therapies-antisens/ 2024-11-27T15:35:42+00:00 https://www.fastfrance.org/apprendre-sur-la-premiere-piste-avec-les-therapies-de-remplacement/ 2024-11-27T15:33:16+00:00 https://www.fastfrance.org/communique-de-necker-sur-les-modalites-dinscription-a-des-essais-cliniques-sur-le-syndrome-dangelman/ 2024-11-27T16:22:37+00:00 https://www.fastfrance.org/reunion-dinformations-sur-lessai-halos-qui-arrive-en-france/ 2024-11-27T15:37:23+00:00 https://www.fastfrance.org/le-recrutement-pour-tangelo-est-termine-et-annonce-de-lessai-clinique-sur-alogabat/ 2024-11-27T15:31:59+00:00 https://www.fastfrance.org/presentation-de-lessai-clinique-aldebaran-et-de-la-molecule-alogabat/ 2024-11-27T15:32:23+00:00 https://www.fastfrance.org/don-de-5-millions-de-dollars-pour-soutenir-les-essais-cliniques-sur-le-syndrome-dangelman/ 2024-11-27T16:30:20+00:00 https://www.fastfrance.org/fast-annonce-la-creation-dune-biotechnologie-transformatx-specialisee-dans-la-therapie-genique-par-lentivirus/ 2024-11-27T16:39:44+00:00 https://www.fastfrance.org/mise-a-jour-du-programme-tangelo-sur-le-rugonersen/ 2022-08-26T12:55:24+00:00 https://www.fastfrance.org/ultragenyx-et-genetx-fournissent-une-mise-a-jour-de-leur-programme-gtx-102/ 2024-11-27T15:33:30+00:00 https://www.fastfrance.org/neuren-commence-la-phase-2-de-lessai-clinique-avec-nnz-2591-pour-le-syndrome-dangelman/ 2024-11-27T16:44:29+00:00 https://www.fastfrance.org/les-ondes-cerebrales-et-ce-quelles-signifient-pour-les-individus-ayant-le-syndrome-dangelman-2/ 2024-11-27T16:13:27+00:00 https://www.fastfrance.org/portrait-de-thomas/ 2022-01-28T14:59:51+00:00 https://www.fastfrance.org/retour-de-barbara-bailus-sur-le-congres-fast-de-decembre/ 2024-11-27T15:37:57+00:00 https://www.fastfrance.org/mise-a-jour-dionis-sur-lessai-clinique-halos/ 2024-11-27T15:33:41+00:00 https://www.fastfrance.org/portrait-de-mael/ 2024-11-27T16:34:02+00:00 https://www.fastfrance.org/genetx-et-ultragenyx-fournissent-une-mise-a-jour-preliminaire-sur-letude-clinique-de-phase-1-2-de-gtx-102-au-canada-et-au-royaume-uni-patients-atteints-du-syndrome-dangelman/ 2024-11-27T16:31:44+00:00 https://www.fastfrance.org/angelman-syndrome-premier-patient-a-recevoir-un-potentiel-traitement-a-oxford/ 2024-11-27T16:30:52+00:00 https://www.fastfrance.org/infographie-mener-des-essais-cliniques-en-france-sur-le-syndrome-dangelman-presentation-de-la-communaute-angelman-de-france/ 2024-11-27T15:29:38+00:00 https://www.fastfrance.org/taysha-gene-therapies-annonce-des-donnees-precliniques-positive-sur-un-aav/ 2024-11-27T15:27:19+00:00 https://www.fastfrance.org/mise-a-jour-du-programme-nnz-2591-de-neuren/ 2024-11-27T16:44:41+00:00 https://www.fastfrance.org/genetx-et-ultragenyx-annoncent-que-la-fda-a-leve-la-suspension-clinique-de-letude-clinique-de-phase-1-2-du-gtx-102-pour-le-traitement-du-syndrome-dangelman-aux-etats-unis/ 2024-11-27T16:31:57+00:00 https://www.fastfrance.org/fast-finance-un-programme-de-recherche-collaborative-pour-soutenir-le-consortium-sur-les-biomarqueurs-et-les-mesures-des-resultats-du-syndrome-dangelman-abom/ 2021-09-18T07:00:52+00:00 https://www.fastfrance.org/ipsen-et-exicure-concluent-une-collaboration-exclusive-ciblant-des-maladies-neurodegeneratives-rares/ 2024-11-27T16:18:25+00:00 https://www.fastfrance.org/fast-a-engage-1-million-de-dollars-pour-la-determination-de-biomarqueurs-et-la-mesure-des-resultats-sur-le-syndrome-dangelman-abom-et-voici-pourquoi-cest-si-important/ 2024-11-27T15:28:05+00:00 https://www.fastfrance.org/temoignage-de-clemence-pour-capucine/ 2024-11-27T15:33:54+00:00 https://www.fastfrance.org/panorama-des-therapies-en-developpement-preclinique-et-clinique-autour-du-syndrome-dangelman/ 2024-11-27T16:12:44+00:00 https://www.fastfrance.org/parents-dune-personne-porteuse-du-syndrome-dangelman-votre-opinion-nous-interesse/ 2024-11-27T16:41:03+00:00 https://www.fastfrance.org/les-perspectives-dune-maman-a-propos-des-genotypes-upd-icd-mosaiques/ 2024-11-27T15:34:11+00:00 https://www.fastfrance.org/les-ondes-deltas-dun-eeg-predisent-de-maniere-robuste-la-fonction-cognitive-dans-le-syndrome-dangelman/ 2024-11-27T15:34:25+00:00 https://www.fastfrance.org/fast-presente-un-nouveau-programme-de-recherche-pour-le-developpement-dun-traitement-potentiel-miarn/ 2024-11-27T15:34:43+00:00 https://www.fastfrance.org/les-nouvelles-capsides-de-voyager-therapeutics-demontrent-une-administration-robuste-a-travers-la-barriere-hemato-encephalique-une-transduction-generalisee-du-snc-chez-des-primates-non-humains/ 2024-11-27T15:41:53+00:00 https://www.fastfrance.org/une-nouvelle-vie-et-un-troisieme-enfant-avec-alix-pour-agrandir-notre-tribu/ 2024-11-27T15:30:58+00:00 https://www.fastfrance.org/genetx-et-ultragenyx-recoivent-lautorisation-de-sante-au-canada-pour-commencer-letude-clinique-du-gtx-102/ 2024-11-27T15:41:17+00:00 https://www.fastfrance.org/fast-organisera-un-sommet-et-un-gala-scientifiques-en-personne-en-2021-et-aussi-en-virtuel/ 2021-05-25T15:39:53+00:00 https://www.fastfrance.org/rapport-financier-dultragenyx-et-mise-a-jour-sur-gtx-102/ 2024-11-27T16:25:07+00:00 https://www.fastfrance.org/lechelle-de-communication-orca-obtient-un-financement-de-la-fda/ 2024-11-27T15:42:51+00:00 https://www.fastfrance.org/neuren-avec-mise-a-jour-du-programme-angelman-sur-nnz-2591/ 2024-11-27T15:35:05+00:00 https://www.fastfrance.org/ccomprendre-lactivation-des-genes-dans-les-genotypes-upd-icd-et-mosaique/ 2024-11-27T16:36:09+00:00 https://www.fastfrance.org/fast-finance-une-ligne-dassistance-pour-les-crises-depilepsie-a-travers-le-programme-du-consortium-de-soins-durgence/ 2024-11-27T15:44:44+00:00 https://www.fastfrance.org/rehabilitation-fonctionnelle-dans-un-modele-de-syndrome-dangelman-apres-traitement-avec-des-cellules-souches-hematopoietiques-transduites-par-lentivecteur/ 2024-11-27T16:38:27+00:00 https://www.fastfrance.org/fast-france-analyse-du-sondage-sur-les-criteres-dimportance-dun-futur-traitement-therapeutique/ 2024-11-27T15:43:09+00:00 https://www.fastfrance.org/cas13_cas9/ 2024-11-27T14:05:24+00:00 https://www.fastfrance.org/mise-a-jour-programme-infrastructure-syndrome-angelman/ 2024-11-27T14:05:40+00:00 https://www.fastfrance.org/ionis-communique-phase1-2/ 2024-11-27T16:22:49+00:00 https://www.fastfrance.org/insync-as-une-collaboration-entre-fast-et-simons-foundation-autism-research-initiative-sfari/ 2024-11-27T16:27:19+00:00 https://www.fastfrance.org/rencontrer-john-schlueter/ 2024-11-27T16:37:39+00:00 https://www.fastfrance.org/iad-fast-france-2021/ 2024-11-27T15:26:07+00:00 https://www.fastfrance.org/changement-a-la-tete-du-conseil-dadministration/ 2024-11-27T16:27:30+00:00 https://www.fastfrance.org/ovid-therapeutics-stars/ 2024-11-27T16:14:22+00:00 https://www.fastfrance.org/ovid-therapeutics-arret-neptune/ 2024-11-27T16:16:29+00:00 https://www.fastfrance.org/webinar-du-10-juin-2020-ovid-therapeutics/ 2024-11-27T16:14:37+00:00 https://www.fastfrance.org/webinar-de-juin-2020-de-roche/ 2024-11-27T16:16:47+00:00 https://www.fastfrance.org/genetx-et-ultragenyx-annoncent-la-presentation-des-donnees-de-phase-1-2-sur-le-traitement-experimental-gtx-102-chez-les-patients-atteints-du-syndrome-dangelman/ 2024-11-27T16:17:06+00:00 https://www.fastfrance.org/genetx-et-ultragenyx-annoncent-des-donnees-intermediaires-positives-de-phase-1-2-sur-le-gtx-102/ 2024-11-27T16:17:20+00:00 https://www.fastfrance.org/genetx-annonce-que-gtx-102-est-approuve-pour-des-essais-cliniques/ 2024-11-27T16:17:41+00:00 https://www.fastfrance.org/la-biotechnologie-genetx-recoit-de-la-fda-la-designation-de-medicament-orphelin-pour-le-syndrome-dangelman/ 2024-11-27T16:23:04+00:00 https://www.fastfrance.org/genetx-nouvelle-biotechnologie-lancee-pour-un-programme-antisens-ciblant-le-syndrome-dangelman/ 2024-11-27T16:23:23+00:00 https://www.fastfrance.org/expression-de-lube3a-via-ladministration-de-vecteurs-lentiviraux-dans-les-cellules-sanguines-pour-traiter-le-sa-2/ 2024-11-27T13:46:57+00:00 https://www.fastfrance.org/expression-de-lube3a-via-ladministration-de-vecteurs-lentiviraux-dans-les-cellules-sanguines-pour-traiter-le-sa/ 2024-11-27T13:49:19+00:00 https://www.fastfrance.org/generation-de-lignees-de-souris-exprimant-lantisens-humain-ube3a/ 2024-11-27T13:48:51+00:00 https://www.fastfrance.org/abom-reponses-auditives-du-cerveau-comme-indicateur-de-la-fonction-cognitive-dans-le-syndrome-dangelman/ 2024-11-27T13:50:31+00:00 https://www.fastfrance.org/effets-therapeutiques-de-ligf2-dans-un-modele-murin-sa-et-evaluation-preclinique/ 2024-11-27T13:51:10+00:00 https://www.fastfrance.org/abom-adaptation-dune-evaluation-neurodeveloppementale-standardisee-pour-sa/ 2024-11-27T13:51:48+00:00 https://www.fastfrance.org/developpement-preclinique-dune-therapie-genique-aav-pour-le-sa/ 2024-11-27T13:52:22+00:00 https://www.fastfrance.org/nouvelles-mesures-du-syndrome-dangelman-dans-un-nouveau-modele-de-rat/ 2024-11-27T13:52:46+00:00 https://www.fastfrance.org/traitement-du-syndrome-dangelman-par-aso-ciblant-ube3a-as/ 2024-11-27T13:53:12+00:00 https://www.fastfrance.org/evaluation-de-linnocuite-tolerance-dune-formulation-nutritionnelle-en-bhb-pour-le-sa/ 2024-11-27T13:54:36+00:00 https://www.fastfrance.org/evaluation-de-potentiels-cerebraux-dans-le-sa/ 2024-11-27T13:55:01+00:00 https://www.fastfrance.org/echelle-de-mesure-de-la-communication-pour-les-patients-sa/ 2024-11-27T13:55:35+00:00 https://www.fastfrance.org/evaluation-du-ligand-du-recepteur-igf-2-l1-et-igf-2-dans-un-modele-rat-sa-sur-le-phenotype-neurocomportemental/ 2024-11-27T13:55:59+00:00 https://www.fastfrance.org/evaluation-de-ligf-2-dans-le-modele-rat-sa/ 2024-11-27T13:56:56+00:00 https://www.fastfrance.org/etudes-sur-les-rongeurs-de-lactivation-du-gene-paternel-ube3a-et-snord-116/ 2024-11-27T13:57:19+00:00 https://www.fastfrance.org/evaluation-du-ligand-du-recepteur-igf-2-l1-et-igf-2-dans-un-modele-de-rat-du-sa/ 2024-11-27T13:57:49+00:00 https://www.fastfrance.org/evaluation-du-traitement-aso-dans-le-modele-rat-sa-avec-aso-dr-scott-dindot/ 2024-11-27T13:58:10+00:00 https://www.fastfrance.org/evaluation-du-traitement-aso-dans-le-modele-rat-sa-avec-analyse-du-liquide-cephalo-rachidien/ 2024-11-27T13:58:30+00:00 https://www.fastfrance.org/evaluation-du-traitement-aso-dans-le-modele-rat-as-en-mesurant-leeg-et-les-phenotypes-de-crise-depilepsie/ 2024-11-27T13:58:55+00:00 https://www.fastfrance.org/projet-pilote-de-faisabilite-dune-therapie-de-remplacement-enzymatique-pour-le-sa/ 2024-11-27T13:59:35+00:00 https://www.fastfrance.org/recherche-translationnelle-pour-un-modele-porc-du-syndrome-d-angelman/ 2024-11-27T13:59:57+00:00 https://www.fastfrance.org/campagne-de-diagnostic-genetique-en-argentine/ 2024-11-27T14:01:19+00:00 https://www.fastfrance.org/2020-2023-modele-souris-sa-deletion/ 2024-11-27T14:02:14+00:00 https://www.fastfrance.org/utilisation-du-dispositif-actimyo-et-caracterisation-de-la-marche-sa/ 2024-11-27T14:02:43+00:00 https://www.fastfrance.org/2020-2022-biorepertoireipsc-organoids/ 2024-11-27T14:03:05+00:00 https://www.fastfrance.org/2020-2022-deletionclasse1/ 2024-11-27T14:03:26+00:00 https://www.fastfrance.org/infrastructuresyndromeangelman/ 2024-11-27T14:03:47+00:00 https://www.fastfrance.org/snord116_ube3a/ 2024-11-27T14:06:59+00:00 https://www.fastfrance.org/voeux-2021/ 2024-11-27T16:29:15+00:00 https://www.fastfrance.org/category/actualite-recherche/ 2025-12-23T08:53:20+00:00 https://www.fastfrance.org/category/uncategorized/ 2025-10-23T08:47:01+00:00 https://www.fastfrance.org/category/actualite-fast/ 2025-02-15T06:48:48+00:00 https://www.fastfrance.org/category/genetx-ultragenyx/ 2024-12-21T09:41:39+00:00 https://www.fastfrance.org/category/ionis/ 2024-11-27T16:37:00+00:00 https://www.fastfrance.org/category/actualite-fast-france/ 2024-12-25T10:55:15+00:00 https://www.fastfrance.org/category/roche/ 2024-11-27T16:16:47+00:00 https://www.fastfrance.org/category/neuren/ 2024-11-27T16:44:41+00:00 https://www.fastfrance.org/category/ovid/ 2024-11-27T16:16:29+00:00